Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. TLTFF


Primary Symbol: V.TLT

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > New BCG-Unresponsive NMIBC Treatment Review Study
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1067)
•••
Comment by StevenBirchon Nov 21, 2024 12:10pm
198 Views
Post# 36324018

RE:New BCG-Unresponsive NMIBC Treatment Review Study

RE:New BCG-Unresponsive NMIBC Treatment Review StudySounds to me like TLT, facing long odds and great difficulty, is...



Eoganacht wrote:
European Urology Oncology
Available online 15 November 2024

David D’Andrea, Hugh Mostafid, Paolo Gontero, Shahrokh Shariat, Ashish Kamat, Alexandra Masson-Lecomte, Maximilian Burger, Morgan Rouprt

Unmet Need in Non–muscle-invasive Bladder Cancer Failing Bacillus Calmette-Gurin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group

"A total of 57 studies published between 1998 and 2024, with 68 unique study arms and consisting of 2589 patients, were identified. The 3-mo overall response rate (ORR) across all studies, complete response rate (CRR) in concomitant carcinoma in situ (CIS) or CIS only disease, and recurrence-free rate (RFR) in papillary disease were estimated to be 52.4% (95% confidence interval [CI]: 45.4–59.2), 52.8% (95% CI: 42.9–62.6), and 26.4% (95% CI: 13.3–45.6), respectively. The 12-mo ORR, CRR, and RFR were estimated to be 78% (95% CI: 52.9–91.8), 27.8% (95% CI: 21.3–35.4), and 25.4% (95% CI: 18.2–34.2), respectively."



The study includes the toxicity events for all 4 BCG-Unresponsive NMIBC approved treatments. TLD1433 had better safety results (zero toxicity events) than all approved treatments.

  Grade 1-2 Grade 3 Grade 4 Grade 5
         
Valrubicin 19% 0% 0% 0%
Adstiladrin (NF) 8.3% 0% 0% 0%
Pembrolizumab 10.9% 2% 0% 0%
Anktiva (NAI) 39% 3.7% 1.2% 1.2%
         
TLD1433 0% 0% 0% 0%



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities